Mersana Therapeutics Appoints Dirk Huebner, M.D., as Chief Medical Officer
Mersana Therapeutics, Inc. (MRSN)
Last mersana therapeutics, inc. earnings: 2/28 06:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
mersana.com/about-mersana
Company Research
Source: GlobeNewswire
CAMBRIDGE, Mass., Nov. 27, 2018 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody drug conjugates (ADCs) targeting cancers in areas of high unmet need, today announced the appointment of Dirk Huebner, M.D., to the position of Chief Medical Officer. Dr. Huebner brings to this position 25 years of drug development experience including significant experience in the development and approval of ADCs. “We are excited for Dirk to join Mersana and bring his deep experience in the field of ADC clinical development. Dirk’s direct experience in the European approval and label expansion activities supporting ADCETRIS® (brentuximab vedotin) will help us build on our leading clinical development organization and prepare for the next steps in the development of XMT-1536 and XMT-1522,” said Anna Protopapas, President and Chief Executive Officer of Mersana. “We believe this deep expe
Show less
Read more
Impact Snapshot
Event Time:
MRSN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MRSN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MRSN alerts
High impacting Mersana Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
MRSN
News
- Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- Mersana Therapeutics, Inc. (NASDAQ: MRSN) was upgraded by analysts at JPMorgan Chase & Co. from an "underweight" rating to a "neutral" rating. They now have a $5.00 price target on the stock.MarketBeat
- AVLX, SGH and ETNB are among pre market losers [Seeking Alpha]Seeking Alpha
- Mersana Therapeutics, Inc. (NASDAQ: MRSN) was upgraded by analysts at Truist Financial Co. from a "hold" rating to a "buy" rating. They now have a $9.00 price target on the stock.MarketBeat
- Mersana Therapeutics, Inc. (NASDAQ:MRSN) Q4 2023 Earnings Call Transcript [Yahoo! Finance]Yahoo! Finance
MRSN
Earnings
- 2/28/24 - Beat
MRSN
Sec Filings
- 4/3/24 - Form 4
- 2/28/24 - Form 8-K
- 2/28/24 - Form 424B5
- MRSN's page on the SEC website